Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Cepheid Receives FDA Clearance For First On-Demand Molecular Diagnostic Test For Clostridium Difficile Infection
Cepheid (Nasdaq: CPHD) announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) C. difficile test, an on-demand molecular diagnostic test designed for 45-minute detection of the bacterium that causes Clostridium difficile infection (CDI). The Xpert C. difficile test is the first test for CDI to deliver both rapid turnaround and a high degree of accuracy.
generic viagra online
Faculty Of Translational Medicine Boosts Support For Biomedical Researchers
A new Faculty of Translational Medicine has been launched to increase support for, and enhance collaboration among researchers as they search for new treatments and diagnostic tests for a range of diseases and conditions. The Faculty is based in the National Institute for Health Research Comprehensive Biomedical Research Center at Guy"s and St Thomas" hospitals and King"s College London.
News of the day
RNC Launches Ads Attacking Moderate Dems; PhRMA Considers Huge Campaign
Current ads sponsored by the Republican National Committee prod Democrats, while a very large planned campaign by drug makers could take flight soon.
Mental Health

Survival In Prostate Cancer Patients >/=70 Years After Radical Prostatectomy And Comparison To Younger Patients

UroToday.com - In the online issue of the World Journal of Urology, a group headed by Professor Markus Hohenfellner compared the outcomes of radical prostatectomy (RP) in men younger and older than age 70 years. They suggest that in well-selected men over age 70 years, the outcomes are comparable. The study cohort consisted of 626 men who underwent RP at their institution between 1990 and 2006. A total of 526 were younger than 70 years old, and 100 were older than 70 years. The majority underwent radical retropubic RP and 46 underwent a perineal approach. The majority had a pelvic lymphadenectomy performed. Median patient age was 64.4 years, median PSA was 8.9ng/ml, and median follow-up was 5.3 years. For the analysis pre-op PSA, pathologic tumor stage, WHO tumor grading, margin status, time of PSA recurrence, time of distant metastatic recurrence, CaP specific and overall survival were considered. ECOG status was >1 in 7% of the older cohort compared to 2.3% of the younger men. While median age was almost 10 years older, percentage of organ-confined cancer, grade, positive lymph node and positive margin status did not differ. Median PSA-free survival was 10.2 years for the young men and not yet reached for the older men. The 10-year PSA-free survival was 51.8% for the young and 57.4% for the older men. The 10-year metastasis-free survival was 86.9% and 89.7% for the 70 year old patients, respectively. The 10-year prostate cancer specific survival was 92.3% and 97.6% for the young and old men, respectively. Median overall survival was 14 and 12.4 years and 10-year overall survival was 78.1% and 71.2% for the 70 year old patients, respectively. In multivariable analysis, there was no difference in any of the categories for clinical outcome where the age was a risk factor for adverse outcome. Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M World J Urol. 2009 Apr 26. Epub ahead of print. doi:10.1007/s00345-009-0414-0 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009